Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
  • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
  • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/63—Steroids; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/08—Solutions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/08—Antiseborrheics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/10—Anti-acne agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/02—Local antiseptics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
  • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q5/00—Preparations for care of the hair
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q5/00—Preparations for care of the hair
  • A61Q5/006—Antidandruff preparations
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q7/00—Preparations for affecting hair growth

Definitions

• the present invention can provide acne and skin trouble improvement effect, skin convergence and pore contraction effect by containing ginsenoside Rg3, and can provide skin color improvement effect, hair growth improvement, white hair improvement, antidandruff and antiseptic effect. It relates to a composition.
• Human skin is the body's primary protective barrier, which protects the body's organs from changes in temperature and humidity, and from external environmental stimuli such as ultraviolet rays and pollutants. Undergo a change. That is, internally, the secretion of various hormones that regulate metabolism decreases, and the function of immune cells and the activity of cells decreases, thereby reducing the biosynthesis of immune proteins and constituent proteins necessary for living organisms.
• free radicals and free radicals increase, thereby reducing the thickness of the skin, increasing wrinkles, reducing elasticity, Skin color becomes dull, skin problems frequently occur, blemishes, freckles and blotch also increase, the color becomes worse and the skin tone becomes darker.
• the skin condition is improved by adding bioactive substances obtained from various known animals, plants, and microorganisms to cosmetics. Efforts have been made.
• Ginsenoside refers to saponin in ginseng. Saponin is a chemical compound called glycoside. Ginsenoside is a name given to mean glyco-side isolated from ginseng to distinguish it from other plant saponins. It is usually named ginsenoside-Rx and the like. Here, “R” means root (Radix or Root) and “x” means o, a, b, c, d, from bottom to top according to the distance (Rf value) of the spot moving on TLC. They are named in order of e, f, g, and h. Ginseng saponin has a variety of effects on the body's function by affecting the central nervous system, endocrine system, immune system, metabolic system.
• G-Rb1 a representative ginsenoside of PPD-based saponins
• G-Rg1 a representative of PPT-based saponins
• Ginseng saponins are panaxadiol-type Ginsenosides (Ra1, Ra2, Ra3, Rb1, Rb2, Rb3, Rc, Rd, Rg3) and panaxtriol-based ginseng depending on the structure of the saponin aglycon. It can be classified into three types such as panacetic acid (Panaxatriol-type Ginsenosides: Re, Rf, Rgl, Rg2) and oleanoic acid-type Ginsenosides.
• panacetic acid Panaxatriol-type Ginsenosides: Re, Rf, Rgl, Rg2
• oleanoic acid-type Ginsenosides oleanoic acid-type Ginsenosides.
• the content of panaxadiol-based saponins in the ginseng root was the highest at 48-60%, followed by the panaxtriol-based saponins at 30-35%, and trace amounts of oleanoline-based saponins.
• the pharmacological action of Rg3, a kind of minor ginsenosides produced during the ginseng process of ginseng can inhibit cancer cell metastasis, inhibit platelet aggregation and antithrombotic action, relax vasculature, experimental liver injury, and anticancer drug resistance.
• oral pharmacological action such as inhibitory effect, the composition of ginsenoside Rg3 as an active ingredient, acne and skin trouble improvement effect, skin convergence and pore contraction effect, skin color improvement effect, hair growth improvement, white hair improvement, No antidandruff and antiseptic effects have been reported.
• the present inventors can provide ginsenoside Rg3, acne and skin trouble improvement effect, skin converging and pore contraction effect, and can provide skin color improvement effect, hair growth improvement, white hair improvement, anti dandruff and antiseptic effect.
• the present invention was completed.
• ginsenoside Rg3 can provide acne and skin trouble improvement effect, skin converging and pore contraction effect, skin color improvement effect, hair growth improvement, white hair improvement, anti dandruff and antiseptic effect It is providing the skin external preparation composition shown.
• the present invention provides a skin external preparation composition for improving acne containing ginsenoside Rg3 as an active ingredient.
• the present invention provides a skin external preparation composition for improving color and skin tone containing ginsenoside Rg3 as an active ingredient.
• the present invention also provides a composition for external application for skin pore reduction containing ginsenoside Rg3 as an active ingredient.
• the present invention also provides a composition for promoting hair growth containing ginsenoside Rg3.
• the present invention also provides a composition for preventing hair loss containing ginsenoside Rg3.
• the present invention also provides a composition for anti-dandruff containing ginsenoside Rg3.
• the present invention also provides a natural preservative composition containing ginsenoside Rg3.
• composition of the present invention can provide acne and skin trouble improvement effect, skin convergence and pore contraction effect by containing ginsenoside Rg3, and can provide skin color improvement effect, hair growth improvement, white hair improvement, antidandruff and antiseptic effect. Can be.
• composition according to the present invention contains ginsenoside Rg3 (Ginsenoside Rg3) as an active ingredient.
• Ginsenoside Rg3 used in the present invention has a structure represented by the following Chemical Formula 1.
• Ginsenoside Rg3 of the present invention can be extracted from plants, may be synthesized according to methods known in the art, and may be commercially available. Ginsenoside Rg3 can also be obtained from ginseng extract.
• the type of ginseng used at this time is not particularly limited, and ginseng, red ginseng, white ginseng, taeguksam, misam and the like can be used.
• the ginseng extract is contained not only in the leachate obtained by leaching and transferring from ginseng, but also in the concentrate obtained by partially or fully concentrating the leachate, or in stagnation, whole, regular, liquid extract and ginseng prepared by drying the concentrate again.
• the chemicals that exert the main effect include all of the plant itself, and extracts from all parts of ginseng, such as stems, roots, leaves, flowers, fruits, can be used and are not limited to extracts of any particular part.
• a method for extracting ginsenoside Rg3 from ginseng extract may use a known method.
• the ginsenoside Rg3 may be isolated from ginseng extract prepared by water or an organic solvent by a method well known in the art in ginseng.
• the organic solvent used in the present invention may be selected from the group consisting of ethanol, methanol, butanol, ether, ethyl acetate, chloroform and a mixed solvent of these organic solvents and water, and preferably 80% ethanol is used.
• the extraction temperature is preferably 10 ⁇ 80 °C, it can be extracted for 3 to 24 hours. If the extraction temperature and extraction time is out of the extraction efficiency may decrease or change of components may occur.
• the composition of the present invention preferably contains the ginsenoside Rg3 in an amount of 0.001 to 50% by weight based on the total weight of the composition. This is because when the content of the active ingredient is less than 0.001% by weight, the efficacy and effect by the above ingredients are weak, and when the amount of the active ingredient exceeds 50% by weight, there is a problem of skin safety or formulation.
• composition of the present invention can be used as an external preparation composition for improving acne, which is excellent in antibacterial effect, in particular, antibacterial effect against acne causing bacteria, and also provides an anti-inflammatory effect.
• composition of the present invention can be used as an external skin composition for improving color and skin tone, and when applied to the skin, it smoothly supplies nutrients to the skin by promoting capillaries and promotes blood circulation and inhibits skin aging to improve color and skin tone. The effect is excellent.
• composition of the present invention can be used as a skin external preparation composition for pore reduction, sebum control and skin trouble improvement, which suppresses excessive secretion of sebum when applied to the skin, promotes free radical removal and collagen synthesis to shrink pores.
• the effect of suppressing skin problems is excellent by reducing the expression of inflammatory factors.
• the composition of the present invention can be used as a composition for promoting hair growth, which promotes hair growth by promoting the transition of the resting hair cycle to the growing hair cycle, and also promotes the production of new hair, as well as promoting healthy hair. It includes growing, and provides the effect of preventing and suppressing the phenomenon of hair falling off from the scalp or the condition of hair growth or thinning.
• the composition of the present invention can be used as a composition for preventing white hair, and increases the MITF expression of melanocytes to activate melanocytes and promote melanin synthesis, thereby preventing the induction of white hair and providing an effect of promoting hair loss.
• composition of the present invention can be used as an anti-dandruff skin external composition, which effectively discharges toxins accumulated in the hair and scalp to cleanse the scalp, inhibit the growth and growth of dandruff bacteria, and prevent the scalp inflammatory reaction, and also active It has an excellent antioxidant effect that inhibits the production and action of oxygen, so it can provide the effect of calming and strengthening the scalp and strengthening its natural defense.
• composition of the present invention can be used as a natural preservative composition, and because it is a natural ingredient, it provides an effect that is excellent in preservative effect and harmless to human body.
• composition according to the invention may be formulated containing a cosmetically or dermatologically acceptable medium or base.
• a cosmetically or dermatologically acceptable medium or base for example emulsions, suspensions, microemulsions, microcapsules, microgranules or ionic (liposomes) and non-obtained by dispersing an oil phase in solution, gels, solids, pasty anhydrous products, aqueous phases.
• It may be provided in the form of an ionic vesicle dispersant or in the form of a cream, skin, lotion, powder, ointment, spray or cone stick. It may also be used in the form of a foam or in the form of an aerosol composition further containing a compressed propellant.
• These compositions can be prepared according to conventional methods in the art.
• topical skin composition of the present invention when used for the prevention of dandruff, hair growth or white hair, it may be formulated as a composition for scalp and hair, and the formulation is not particularly limited, for example, hair tonic, hair nourishing cosmetics, scalp It can be formulated as a treatment, hair treatment, hair shampoo, hair rinse, hair lotion or scalp hair combination treatment and the like.
• the composition according to the present invention is a fatty substance, an organic solvent, a dissolving agent, a thickening agent, a gelling agent, a softening agent, an antioxidant, a suspending agent, a stabilizer, a foaming agent, a fragrance, a surfactant, water, an ionic or nonionic.
• a fatty substance an organic solvent, a dissolving agent, a thickening agent, a gelling agent, a softening agent, an antioxidant, a suspending agent, a stabilizer, a foaming agent, a fragrance, a surfactant, water, an ionic or nonionic.
• adjuvants conventionally used in the
• composition of the present invention may contain a skin absorption promoting substance to increase the skin improving effect.
• test examples and formulation examples are provided only for the purpose of illustration to help the understanding of the present invention is not limited to the scope and scope of the present invention by the following examples.
• Ginsenoside Rg3 for testing the efficacy of the composition of the present invention was purchased from Ambo laboratory.
• Nutritional cream was prepared in a conventional manner according to the composition of Table 1 (unit: wt%).
• LDPI Laser Doppler Perfusion Imager; periscan PIM II, Perimed (stochholm, Sweden)
• LDPI is a well-known and currently used device for measuring blood circulation in the skin, and is a very sensitive device that can measure not only the speed and amount of blood in capillaries of the skin but also the flow in the small arteries and the venous veins.
• the cosmetic composition according to the present invention significantly increased the skin blood flow than Comparative Formulation Example 1 containing no ginsenoside Rg3, it was confirmed that the blood color is improved by promoting the blood circulation. . This ultimately suggests that the cosmetic composition containing ginsenoside Rg3 according to the present invention can contribute effectively to the skin's nutrient delivery, inhibit skin aging and delay.
• Comparative Formulation Example 1 which does not contain ginsenoside Rg3 according to the present invention does not show a significant skin tone improvement effect, while Formulation Example 1 containing ginsenoside Rg3 as an active ingredient than before use It was confirmed that the skin tone after use is much improved.
• Ginsenoside Rg3 was measured by comparing collagen biosynthesis promoting effect with TGF- ⁇ .
• fibroblasts were seeded by 10 5 per hole in 24 wells and cultured until 90% growth. This was incubated in serum-free DMEM medium for 24 hours, and then treated with 10 ng / ml of ginsenoside Rg3 and TGF- ⁇ of the present invention dissolved in serum-free medium and incubated in a CO 2 incubator for 24 hours. These supernatants were removed and procollagen increased or decreased using a procollagen type (I) ELISA kit (procollagen type (I); # MK101, TAKARA (Shiga, Japan)). The results are shown in Table 4, and the synthetic ability of collagen was compared with the non-treated group as 100.
• procollagen type (I) ELISA kit procollagen type (I); # MK101, TAKARA (Shiga, Japan
• ginsenoside Rg3 according to the present invention was confirmed to exhibit a high level of collagen synthesis ability higher than the positive control TGF- ⁇ . Therefore, it was confirmed that ginsenoside Rg3 according to the present invention can reduce the enlarged pores by increasing the amount of collagen production around the pores.
• Comparative Formulation Example 1 does not have a pore reduction effect, but in the case of Formulation Example 1 exhibits a pore reduction effect that can be visually confirmed, ginsenoside Rg3 according to the present invention reduces the size of the pores It was found that the effect was excellent.
• HEK293 cells were transfected with p3 ⁇ FLAG-CMV-5 ⁇ R2 and cultured in a 24 well plate at 2.5 ⁇ 10 5 cells per well (Park et al., 2003, JDS. Vol. 31, pp. 191-98). The next day, a new medium with enzyme substrate and inhibitor was added. 0.05 ⁇ Ci [ 14 C] testosterone (Amersham Pharmacia biotech, UK) was used as the substrate of the medium.
• ginsenoside Rg3 was added thereto and incubated for 2 hours at 37 ° C. in a 5% CO 2 incubator. At this time, the ginsenoside Rg3 was used as a negative control group, the pinasteride was used as a positive control group. Thereafter, the culture medium was collected, the steroid was extracted with 800 ⁇ l ethyl acetate, the organic solvent layer was separated, dried, and the remaining residue was dissolved in 50 ⁇ l ethyl acetate.
• the silica plastic sheet kieselgel 60 F254 was developed using ethyl acetate-hexane (1: 1) as a solvent.
• 5 ⁇ -reductase which converts testosterone to dihydrotestosterone, binds to a receptor protein in the cytoplasm, enters the nucleus, activates sebaceous gland cells, promotes differentiation, and hypersecretes sebum in sebaceous glands.
• ginsenoside Rg3 effectively inhibited the conversion of testosterone to dihydrotestosterone, effectively inhibiting the activity of, and had a superior inhibitory effect than finasteride, which is known to inhibit the activity of 5 ⁇ -reductase.
• finasteride which is known to inhibit the activity of 5 ⁇ -reductase.
• Formulation Example 2 and Comparative Formulation Examples 2 to 3 were prepared according to the ingredients and the contents (% by weight) shown in Table 8 below. Specifically, Formulation Example 2 is a combination of ginsenoside Rg3, Comparative Formulation Example 2 does not contain any active ingredients for improving acne skin, Comparative Formulation Example 3 is a standard to be used as a reference for antimicrobial activity It contains erythromycin, which is widely used as an acne treatment.
• the preparation method of Formulation Example 2 and Comparative Formulation Examples 2-3 is as follows.
• the components of phase A in Table 8 were completely dissolved, and the components of phase B were completely dissolved in a separate dissolution tank, and then mixed and solubilized by adding phase B to phase A.
• the ingredients of phase C were added thereto according to the blending ratios described in Table 8 to homogenize the mixing and then filtered to prepare the compositions.
• Table 8 division Formulation Example 2 Comparative Formulation Example 2 Comparative Formulation Example 3 A Deionized Water To 100 To 100 To 100 EDTA-2Na 0.02 0.02 0.02 glycerin 5.0 5.0 5.0 B ethanol 2.0 2.0 2.0 PEG-60 hydrogenated castor oil 0.4 0.4 0.4 Perfume 0.04 0.04 0.04 C Ginsenoside Rg3 5.0 - - Erythromycin - - 5.0
• the antibacterial test method for acne bacteria was as follows.
• Propionibacterium acnes was used as a culture broth inoculated in BHI broth and anaerobic culture.
• test bacteria 0.15 ml of the test bacteria was added to 15 ml of BHI broth (pH 6.8) or LB broth (pH 4.5) and mixed well as a dilution solution.
• the antibacterial activity test results for acne bacteria are shown in Table 9 below. MIC is expressed in terms of the concentration of the active ingredient contained in the formulation.
• a mouse fibroblast cell line, 3T3-L1 cells was loaded with DMEM (Dulbeco's modified eagle's medium, GIBCO BRL, Life Technologes) medium containing 10% fetal bovine serum (FBS).
• DMEM Dulbeco's modified eagle's medium, GIBCO BRL, Life Technologes
• FBS fetal bovine serum
• the well culture plates were attached at 1 ⁇ 10 5 cells / well. After 2 days, it was again exchanged with fresh DMEM (containing 10% FBS) medium and incubated for 2 days.
• the cultured cells were then induced to differentiate into DMEM (containing 10% FBS) containing 1 ⁇ g / ml insulin, 0.5 mM IBMX and 0.25 ⁇ M dexamethasone, and ginsenoside Rg3 and caffeine. After 2 days of treatment 50 ⁇ M was replaced with DMEM containing insulin and incubated for 5 days. After 5 days, the cells were exchange
• ginsenoside Rg3 used in the present invention can be seen that not only the amount of fat accumulated in adipocytes, but also has a superior lipid synthesis inhibitory effect than caffeine, a known lipid synthesis inhibitor. . Therefore, sebum is reduced by inhibiting lipid synthesis, thereby suppressing the occurrence of acne.
• Formulation Example 2 did not recur acne compared to Comparative Formulation Example 2, it can be seen that there is an excellent effect on the overall acne improvement.
• Comparative Formulation Example 3 containing an antimicrobial activity standard shows an acne-improving effect, but due to its strong skin irritation in use, it may not be suitable for long-term use, but the composition according to the present invention has no irritation for long-term use. Even appeared to be appropriate.
• a shampoo in the composition of Table 12 To prepare a shampoo in the composition of Table 12. Specifically, the surfactant and ethylene glycol distearate are added to purified water, heated to 80 ° C., uniformly dissolved, and then slowly cooled to 40 ° C. under stirring, and the active ingredient and preservative according to the present invention are added to the mixture. A viscosity modifier, a perfume, and a hair conditioner were added and mixed, followed by cooling to room temperature under stirring.
• Example 3 containing ginsenoside Rg3 shows a better effect in preventing scalp itch.
• Hair loss treatment of minoxidil is known as mitochondrial potential potassium ion channel openers (K ATP channel opener), a representative drug used in the treatment of androgenetic alopecia.
• K ATP channel opener mitochondrial potential potassium ion channel openers
• To evaluate the mechanism of minoxidil the treatment of toltamide (SIGMA AlDRICH, T0891), which blocks the K ATP channel in fibroblasts constituting the dermis of the scalp, inhibits cell proliferation, and then opens potassium ion channels to allow cell proliferation. A recovering test method was used.
• a mouse embryonic fibroblast cell line (NIH3T3) cell line was used.
• the cell line is a cell line in which the fibroblast cell line isolated from NIH Swiss mouse embryo was naturally immortalized by 3T3 protocol.
• the cell line was incubated in DMEM (Gibco BRL, Gaithersburg, MD, USA) containing 10% FBS for 24 hours in an incubator maintained at 5% CO 2 , 37 °C.
• NIH3T3 was placed in a 96-well plate and incubated in a 37 ° C.
• Table 16 sample Melanin Synthesis (%) DMSO (0.1%) 100 IBMX (100 ⁇ M) 120 Ginsenoside Rg3 (10 ppm) 110 Ginsenoside Rg3 (50 ppm) 120
• Rg3 was treated with 10 ppm, and then incubated at 37 ° C. for 24 hours, 48 hours, and 72 hours to obtain protein.
• the protein thus obtained was subjected to western blot using MITF and tyrosinase antibody. Protein extraction and Western blot were usually performed by standard methods used by those skilled in the art. After western blot the results are shown in Table 17 below by comparing the negative control to 100.
• Antimicrobial experiments were conducted to evaluate the antimicrobial activity of ginsenoside Rg3.
• the specific experimental method is as follows.
• Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa strains used in the experiment were tested on Tryptic Soy Broth.
• Candida albicans and Aspergillus niger strains were cultured in Sabouraud Dextrose Broth. Incubate 1/100 (Candida albicans) in each medium The strain was diluted 1/10) was used as the test bacteria.
• Aspergillus niger used a spore suspension prepared to be 2 ⁇ 10 8 cfu / ml as the test cell solution.
• test bacteria 0.15 ml of the test bacteria was added to 15 ml of each medium, and a well mixed solution was used as a diluting solution.
• 16 ⁇ l of 10 ppm of ginsenoside Rg3 was added to the first row of a 96 well plate, and 184 ⁇ l of the diluted solution was added thereto. The remaining wells were added with 100 ⁇ l of dilution solution. After mixing well the mixture of the first row, 100 ⁇ l was taken in the second row, mixed well, and then diluted 100 times by taking 100 ⁇ l again in the third row.
• Staphylococcus aureus Escherichia coli, Pseudomonas aeruginosa, Candida albicans, Aspergillus niger, in a 32 ° C. thermostat. niger was incubated in a 25 °C thermostat.
• Table 18 Sample Minimum Inhibitory Concentration (MIC),% Sedona Monas Aruginosa Staphylococcus aureus Escherichia Coli Candida Albicans Aspergillus Niger Ginsenoside Rg3 0.18 0.05 0.142 > 3 > 1
• ginsenoside Rg3 exhibits antimicrobial activity against various strains, through which it can be predicted that ginsenoside Rg3 can act as a natural preservative or antimicrobial agent in the composition.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Dermatology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Molecular Biology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Birds (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Cosmetics (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (3)

Applications Claiming Priority (2)

Publications (1)

Family

ID=51792149

Family Applications (1)

Country Status (5)

Cited By (1)

Families Citing this family (7)

Citations (5)

Family Cites Families (18)

• 2013
  • 2013-04-24 KR KR1020130045119A patent/KR102021463B1/ko active IP Right Grant
• 2014
  • 2014-04-24 WO PCT/KR2014/003596 patent/WO2014175678A1/ko active Application Filing
  • 2014-04-24 CN CN201480032940.7A patent/CN105283189A/zh active Pending
  • 2014-04-24 CN CN201710971175.0A patent/CN107661344A/zh active Pending
  • 2014-04-24 CN CN201710970663.XA patent/CN107595659A/zh active Pending
  • 2014-04-24 TW TW103114697A patent/TWI636796B/zh active
  • 2014-04-24 CN CN202010041076.4A patent/CN111135110B/zh active Active
• 2016
  • 2016-06-27 HK HK16107447.6A patent/HK1219420A1/zh unknown

Patent Citations (5)

Also Published As

Similar Documents

Legal Events